(Q30660658)

English

Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

multicenter clinical trial

0 references

arterial hypertension

1 reference

based on heuristic

inferred from title

essential hypertension

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Elliott WJ

1

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Calhoun DA

2

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

DeLucca PT

3

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Gazdick LP

4

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Kerns DE

5

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Zeldin RK

6

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

publication date

1 August 2001

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

1166-1179

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Valsartan. A review of its pharmacology and therapeutic use in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuation of initial antihypertensive medication after 1 year of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced ambulatory heart rate response to physical work and complaints of fatigue among hypertensive males treated with beta-blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Amlodipine, enalapril, and dependent leg edema in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin II receptor blockers. A new class of antihypertensive drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Human blood pressure determination by sphygmomanometry

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin II antagonists for hypertension: are there differences in efficacy?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Renal effects of angiotensin II receptor blockade in normotensive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Trials to assess equivalence: the importance of rigorous methods

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980099-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(01)80099-0

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30660658&oldid=1964865239"